<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-69718</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:description xml:lang="en">Case report: A 52-year-old woman with advanced colorectal cancer was referred to us for treatment of Cetuximab-related ocular side-effects.Discussion: Cetuximab is a monoclonal antibody that specifically blocks epidermal growth factor receptor activity. It has recently been approved to treat some tumors such as metastatic colorectal cancer and some ORL cancers. Tolerance to it seems to be better than that to the classic chemotherapeutic agents. However, it has several side-effects. Cetuximab-related eyelid toxicity has been recently described, though the pathogenesis has not yet been clearly established (AU)</dc:description>
<dc:creator>Pastor-Pascual, F</dc:creator>
<dc:creator>España-Gregori, E</dc:creator>
<dc:creator>Aviñó-Martínez, J</dc:creator>
<dc:creator>Ramírez-Soria, MP</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Mujer de 52 años diagnosticada de adenocarcinoma colorrectal, remitida a nuestro servicio por presentar tras iniciar tratamiento con Cetuximab reacción adversa palpebral. Discusión: El Cetuximab es un anticuerpo monoclonal cuya diana es el receptor del factor de crecimiento epidérmico. Ha sido incorporado recientemente al tratamiento de tumores, principalmente el cáncer colorrectal metastático y los tumores del área otorrinolaringológica. Su tolerancia es en principio mejor que la de los agentes quimioterápicos clásicos. Sin embargo, no está exento de efectos secundarios. La toxicidad palpebral asociada a Cetuximab ha sido recientemente descrita, por lo que la patogenia no está establecida claramente (AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;83(11): 665-668, nov. 2008. ilus</dc:source>
<dc:identifier>ibc-69718</dc:identifier>
<dc:subject>^d238^s22012</dc:subject>
<dc:subject>^d238^s22036</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d920</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d4896^s22021</dc:subject>
<dc:subject>^d1787^s22016</dc:subject>
<dc:subject>^d920^s22002</dc:subject>
<dc:subject>^d23595^s22009</dc:subject>
<dc:subject>^d4896^s22000</dc:subject>
<dc:subject>^d1787^s22012</dc:subject>
<dc:subject>^d4896^s22002</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d23595^s22036</dc:subject>
<dc:subject>^d23595^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>200811</dc:date>
</metadata>
</record>
</ibecs-document>
